ClinicalTrials.gg
CompletedNCT03549260Updated Feb 18, 2019

Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C Reduction

A Phase 2 interventional study of LIB003 in LDL Cholesterol, sponsored by LIB Therapeutics LLC. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-18.

Sponsored by LIB Therapeutics LLC · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2018, 8 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Study to assess the LDL-C lowering efficacy of different doses of LIB003 administered every 4 weeks in subjects on stable statin and/or ezetimibe therapy

Read the detailed description

Randomized, Double-Blind, Placebo-Controlled, Phase 2 study to assess the LDL-C lowering efficacy at Week 12 of various doses of LIB003 administered subcutaneously (SC) every 4 weeks (Q4W) in patients with hypercholesterolemia on stable diet and oral LDL-C-lowering drug therapy.

02

Conditions studied

  • LDL Cholesterol

Keywords

  • low density lipoprotein cholesterol
  • PCSK9
03

In context

Lead sponsor

LIB Therapeutics LLC is the lead sponsor of 13 studies on the registry; 3 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 2 (25%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, 18 years of age or older
  2. Elevated LDL-C on current lipid lowering therapy and; prior atherosclerotic cardiovascular disease (ASCVD) event or evidence of ASCVD or without ASCVD but at high risk for ASCVD based on AHA/ACC CVD risk calculator, or aged 40 years and older with diabetes and moderate- to high-intensity statin, or pre-treatment LDL-C 190 mg/dL or greater or heterozygous familial hypercholesterolemia (HeFH)
  3. (BMI) between 18 and 40 kg/m2

Exclusion criteria

Exclusion Criteria:

  1. Females of not using or willing to use an effective form of , or pregnant or breastfeeding, or who have a positive serum pregnancy test at screening
  2. Homozygous familial hypercholesterolemia
  3. LDL or plasma apheresis within 2 months; lomitapide or mipomersen within 12 months
  4. Uncontrolled cardiac arrhythmia, myocardial infarction, unstable angina, PCI, CABG, or stroke within 3 months prior to enrollment
  5. Uncontrolled cardiac arrhythmia, myocardial infarction, unstable angina, PCI, CABG, or stroke within 3 months prior to enrollment
  6. Newly diagnosed or poorly controlled ( >9%) type 2 diabetes
  7. Uncontrolled hypertension
  8. Moderate to severe renal insufficiency
  9. Elevated liver function test at screening
  10. Uncontrolled cardiac arrhythmia or prolonged on
  11. A history of prescription drug abuse, illicit drug use, or alcohol abuse
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    LIB003 150 mg or matching placebo

    SC LIB003 150 mg or placebo every 4 weeks

    Biological: LIB003

  • Experimental
    LIB003 300 mg or matching placebo

    SC LIB003 300 mg or placebo every 4 weeks

    Biological: LIB003

  • Experimental
    LIB003 350 mg or matching placebo

    SC LIB003 350 mg or placebo every 4 weeks

    Biological: LIB003

Interventions

  • BiologicalLIB003

    LIB003 or placebo

06

What researchers measure

Primary outcomes

  1. Percent reduction in Low Density Lipoprotein Cholesterol (LDL-C) at week 12

    Change in serum LDL-C from baseline after 12 weeks

    Time frame: baseline to 12 weeks

Secondary outcomes

  1. The incidence and severity of treatment emergent adverse events (TEAEs)

    safety and tolerability will be based on the incidence and severity of treatment emergent adverse events

    Time frame: baseline to 12 weeks

  2. Percent reduction in apolipoprotein B (Apo B) at week 12

    Change in serum Apo B from baseline after 12 weeks

    Time frame: baseline to 12 weeks

  3. Percent reduction in lipoprotein (a) [Lp(a)] at week 12

    Change in serum Lp(a) from baseline after 12 weeks

    Time frame: baseline to 12 weeks

  4. Percent reduction in free PCSK9 at week 12

    Change in serum free PCSK9 from baseline after 12 weeks

    Time frame: baseline to 12 weeks

  5. Presence of anti LIB003 antibodies (ADAs)

    Measurement of ADAs at baseline and various intervals

    Time frame: baseline to 12 weeks

07

Study locations

5 sites
  • Midwest Institute For Clinical Research
    Indianapolis, Indiana 46260, United States
  • Louisville Metabolic and Atherosclerosis Research Center
    Louisville, Kentucky 40213, United States
  • Sterling Research Group
    Cincinnati, Ohio 45219, United States
  • The Lindner Research Center
    Cincinnati, Ohio 45219, United States
  • Metabolic & Atherosclerosis Research Center (MARC)
    Cincinnati, Ohio 45227, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in Nov 2018, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2018
First posted
Jun 7, 2018
StartActual
May 22, 2018
Primary completionActual
Nov 9, 2018
CompletionActual
Nov 30, 2018
Last update
Feb 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03549260
Lead sponsor
LIB Therapeutics LLC
Collaborators
Medpace, Inc.
Responsible party
Sponsor
First posted
Jun 7, 2018
Start date
May 22, 2018
Primary completion
Nov 9, 2018
Completion
Nov 30, 2018
Last update
Feb 18, 2019

Study contacts

Evan A Stein, MD
study director · LIB Therapeutics LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lerodalcibep

Start the discussion